We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 26, 2019

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
JAMA 2019 Sep 19;322(12)1155-1166, J Rosenstock, SE Kahn, OE Johansen, B Zinman, MA Espeland, HJ Woerle, E Pfarr, A Keller, M Mattheus, D Baanstra, T Meinicke, JT George, M von Eynatten, DK McGuire, N Marx

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading